Skip to main
  1. Stocks
  2. Phathom Pharmaceuticals
  3. Forecast
PHAT

Phathom Pharmaceuticals (PHAT) Stock Forecast & Price Target

Phathom Pharmaceuticals (PHAT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Phathom Pharmaceuticals is attractive because VOQUEZNA is the first and only approved U.S. P-CAB, giving it a differentiated position in a large GERD market where roughly 110 million PPI prescriptions are filled annually and about 40% of patients may be PPI-inadequate responders. Its clinical profile is compelling, with rapid, durable acid suppression, 93% healing versus 85% for lansoprazole in erosive esophagitis, and improving real-world adoption as access frictions ease through targeted GI selling and BlinkRx support. Fundamentally, the setup also offers upside from a potential 2027 tegoprazan launch, Phase 2 EoE expansion, and exclusivity through 2032, while revenue is guided to $310–325 million in 2026 and EBITDA profitability is expected that year.

Bears say

Phathom Pharmaceuticals is facing a tougher-than-expected commercial ramp for VOQUEZNA, as physician access friction has slowed GERD prescribing and pushed out the expected reacceleration in 2026, which could reduce peak sales expectations. Competitive pressure is also building from Sebela’s tegoprazan, submitted on January 9, 2026 with anticipated US approval in January 2027, and its Phase 3 data across more than 2,000 patients showed superiority versus lansoprazole that could pressure Phathom’s share and pricing. Financially, the $300MM Hercules term loan is secured by nearly all assets, requires minimum cash of 20% of principal, and could force costly renegotiation or acceleration if covenants are missed.

Phathom Pharmaceuticals (PHAT) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Phathom Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Phathom Pharmaceuticals (PHAT) Analyst Forecast & Price Prediction

Get the latest Phathom Pharmaceuticals (PHAT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Phathom Pharmaceuticals (PHAT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Phathom Pharmaceuticals (PHAT) Forecast

Analysts have given Phathom Pharmaceuticals (PHAT) a Buy based on their latest research and market trends.

According to 5 analysts, Phathom Pharmaceuticals (PHAT) has a Buy consensus rating as of Nov 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Phathom Pharmaceuticals (PHAT)


Phathom Pharmaceuticals (PHAT) Analyst Forecast & Price Prediction

Get the latest Phathom Pharmaceuticals (PHAT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Phathom Pharmaceuticals (PHAT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PHAT stock data and trends